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Abstract 
Infections  are  still  an  important  cause  of
mortality  and  morbidity  in  pediatric  cancer
patients.  Most  of  the  febrile  episodes  in
immunocompromised  patients  are  classified
as a fever of unknown origin (FUO) while bac-
teria are the more frequent causes of docu-
mented  infections.  Viral  infections  are  also
feared during chemotherapy but less data are
available on their incidence and morbidity. We
reviewed the literature on incidence, morbidi-
ty, and mortality of viral infections in children
undergoing chemotherapy and discussed the
evidence concerning the prophylaxis and the
therapy. 
Introduction
During  the  last  decades,  survival  rates  in
pediatric cancer have continuously increased.
Infections are an important cause of morbidity
and  mortality  for  children  with  malignancy.
Infectious complications not only contribute to
mortality  but  also  prolong  hospitalisation,
delay chemotherapy delivery, affect quality of
life  and  increase  healthcare  utilization  and
costs.
The  most  frequent  causal  pathogens  of
febrile neutropenia (FN) are bacteria or fungi;
they are identified and confirmed by culture in
only 25-30% of the cases. In other 15-25% of
patients with FN, bacterial or fungal infections
are suspected on clinical findings. The remain-
ing  50%  of  cases  are  classified  as  fever  of
unknown origin (FUO) and may be caused by
other pathogens, namely virus, that are more
difficult to detect by conventional methods.1
Generally viral infections are suspected on
the basis of clinical data, laboratory findings
and lack of other identified sources of fever;
nevertheless, often it is difficult to confirm a
suspected viral etiology on the basis of clinical
findings with the isolation of the virus.2
Understanding the prevalence and the char-
acteristics of viral infections can improve the
treatment  of  febrile  episodes  in  cancer
patients.  Unfortunately,  very  few  studies  on
viral diseases in pediatric cancer patients have
been published.
The respiratory viruses are one of the more
frequent  cause  of  viral  infection  in  cancer
patients and are implicated in the commonest
seasonal-related  community-acquired  infec-
tions. Christensen observed in a prospective
follow-up study all the febrile episodes during
12 months in a pediatric oncology department;
nineteen  viral  infections  were  diagnosed  in
250 febrile episodes. By molecular diagnosis,
he increased the microbiologic verification of
infections  to  35%.  Overall,  viral  infections
were rare but he reported a fatal complication
caused  by  respiratory  syncytial  virus  (RSV).
Moreover he found a lower number of febrile
episodes in solid tumor patients while the viral
infections were more frequent in this group
than in patients with hematologic malignan-
cies.3
Katsimpardi  et  al  collected  retrospectively
all infectious episodes in children with acute
lymphoblastic  leukemia  (ALL)  from  a  single
institution, i.e. 610 episodes over 6 years. The
objective  was  to  assess  the  type,  frequency,
severity  and  outcome  of  all  infectious
episodes. Viral infections were diagnosed in
about  10%  of  episodes.  The  most  frequent
diagnosis were varicella-zoster (VZV) and her-
pes simplex virus (HSV) infections. Most of
the  severe  infections  occurred  during  the
induction  therapy  (bacteremia  and  FUO),
while viral infections were more common dur-
ing maintenance treatment.4
In another study, viral pathogens were iden-
tified in 34% of the episodes of FN.5 This study
compared  patients  with  FUO  with  patients
affected by viral infections; patients with FUO
had shorter duration of fever and hospitalisa-
tion; only few cases developed clinical compli-
cation. This study described less FUO (53% of
total FN) and more diagnoses of viral infec-
tions compared with other similar observation-
al studies.6 The majority of bacteremia find-
ings diagnosed by blood culture were detected
within 24 hours and most FUO (66%) had fever
for less than 24 hours. The authors emphasize
that  increasing  detection  of  viral  infections
can improve treatment of FN, establishing dif-
ferent, risk based approaches for management
of fever in pediatric cancer patients.
Despite the paucity of studies on epidemio-
logical  aspects  of  viral  diseases  in  children
undergoing  chemotherapy,  literature  reports
many case descriptions of severe or lethal viral
infections. These reports are in opposition with
the  common  opinion  that  viruses  are  quite
harmless in cancer patients.7-11 We reviewed lit-
erature on incidence, morbidity and mortality of
viral infections in children undergoing chemo  -
therapy and discussed the evidence concerning
the prophylaxis and the therapy.
Methods
For the literature search we used the key
words  prophylaxis,  viral  infections,  pediatric
malignancy and therapy, viral infections, pedi-
atric  malignancy.  The  literature  search  was
limited  to  English  language  papers  and  the
period analyzed was from 1 January 1990 to 31
July 2010. Reference list of papers selected by
literature search was also used as source, if
necessary. The results of the search were first
discussed and scored by the authors and then
presented for the final discussion and approval
to a expert meeting held in Florence on 12 and
13 October 2010 where the representatives of
centers  belonging  to  Italian  Association  of
Pediatric  Hematology  Oncology  (AIEOP)
attended.  The  scoring  system  proposed  by
Infectious  Diseases  Society  of  America  was
adopted to define the quality of evidence and
strength of recommendations (Table 1).
Varicella-Zoster virus 
Like other herpesvirus infection, varicella-
zoster virus (VZV) can remain latent after pri-
mary infection; immunosuppression caused by
chemotherapy increases the likelihood of reac-
tivation. Before the introduction of acyclovir
and hyper-immune immunoglobulin, mortality
caused  by  disseminated  varicella  was  high.
Moreover, in ALL patients who had developed
previously VZV, Herpes zoster may occur up to
25%. Prophylaxis with VZV immunisation has
decreased this complication.
Leukemic  patients  and  parents  should  be
informed about VZV transmission and advised
of strategies on how to avoid exposure (AIII).
Family  members,  household  contacts  and
healthcare workers known to be VZV-seroneg-
ative or children with no history of VZV infec-
tion should be given varicella vaccine (BIII).
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All  patients  with  varicella  or  disseminated
zoster  should  be  placed  under  airborne  and
contact isolation. The isolation should contin-
ue as long as the rash remains vesicular and
until all lesions are crusted (BIII).
Passive  immunization  with  human
Varicella-zoster  immunoglobulin  (VZIG)
should be given as soon as possible after expo-
sure  (<96  h)  to  VZV-seronegative  leukemic
patients  on  chemotherapy  (AII).  Where  pas-
sive immunization is not available, post-expo-
sure  prophylaxis  with  acyclovir  starting  7-9
days  after  exposure  is  recommended  (20
mg/kg four times daily for 7 days – max 800
mg/dose) (AIII). If a second exposure occurs
more  than  21  days  after  a  dose  of  passive
immunization or after the administration of
the antiviral prophylaxis, a prophylaxis should
be readministered (CIII).
In  case  of  disease,  antiviral  treatment
reduces the duration of viral replication and
clinical  manifestation.  Patients  treated  for
leukemia who have a varicella-like rash should
be  started  immediately  on  i.v.  acyclovir  20
mg/kg every 8 h for 5-10 days (AI). Therapy
(i.v./oral) should be given for at least 7 days
and  to  be  continued  until  2  days  after  all
lesions are crusted (AI). Vigilance for the pos-
sibility of visceral VZV disease without muco-
cutaneous  manifestations  (for  example,  in
cases of encephalitis, pneumonitis or hepati-
tis) is needed, and i.v. acyclovir should be con-
sidered  in  such  cases  (AIII).  Foscarnet  (60
mg/kg every 12 h i.v.) or cidofovir (5 mg/kg
once a week for 2 weeks, then (if still needed)
once  every  2  weeks  combined  with  pro  -
benecide and i.v. hydration) are alternatives
for anti-VZV treatment in a case of acyclovir-
resistant VZV infection (AIII).12-14
Herpes simplex virus
HSV (herpes simplex virus) (type 1 > type
2) commonly cause mucocutaneous lesions in
patiens with hematologic malignancies. HSV
reactivation is frequent both in patients with
acute leukemia during induction chemothera-
py and in SCT recipients. The incidence of HSV
lesions  among  seropositive  patients  during
chemothe  rapy is high in many observational
studies in adults. In a prospective cohort study
in pediatric oncology patients, HSV was detect-
ed from mouth swab and blood specimen dur-
ing FN; prevalence of HSV infection was low,
oral HSV was associated with longer median
duration of mucositis but was not associated
with  prolonged  fever  or  neutropenia.  It  is
unknown whether early intervention with acy-
clovir can reduce the duration of mucositis.15
Primary HSV infection in patients treated
for  leukemia  is  unusual,  and  antiviral  drug
prophylaxis is thus not recommended in HSV-
seronegative  leukemic  patients  during
chemotherapy (DIII).
ALL patients during the phase of induction
that are HSV-seropositive may be considered
for  antiviral  drug  prophylaxis  with  acyclovir
(level of recommendation CIII). The therapy of
choice for severe mucocutaneous or visceral
HSV  disease  is  intravenous  acyclovir 
250 mg/m2 or 5 mg/kg every 8 h for 7-10 days
(AI). Oral acyclovir for 10 days (AI) is consid-
ered as alternative for less serious manifesta-
tions of HSV disease; for adult patients only
valaciclovir  p.o.  for  10  days  (BIII)  or  famci-
clovir p.o. for 10 days (BIII) may be considered
as well. For HSV pneumonia or HSV meningitis
and encephalitis, a higher dose of i.v. acyclovir
500 mg/m2 or 10 mg/kg every 8 h for 14-21 days
should be considered (CIII).13
Cytomegalovirus 
Cytomegalovirus  (CMV)  is  a  significant
cause of morbidity and mortality in patients
who had undergone hematopoietic stem cell
transplantation (HSCT) but it has increasingly
reported also in leukemic patients treated with
fludarabine or monoclonal antibodies (alem-
tuzumab). We adopted the ECIL recommenda-
tions (European Conference on Infections in
Leukemia)  for  CMV  prophylaxis  in  patients
non-SCT (Table 2).
Cytomegalovirus therapy
Patients  with  symptoms  compatible  with
CMV but without manifest organ involvement
should be carefully assessed. In patients with
suspected CMV organ involvement, the risks
and benefits of antiviral therapy should be con-
sidered before a decision is made. The choice
of an antiviral agent will depend on the indi-
vidual patient, the risk for progression to CMV
disease and the risk for side effects of the cho-
sen  drug.  Limited  data  are  available  about
intravenous immunoglobulin i.v. (IVIG). and it
seems not add benefit in addition to antiviral
therapy; the evidence for their use is CII.16-18
For therapy see Table 3.
Epstein-barr virus
We adopted the ECIL recommendation for
Epstein-barr virus (EBV). Routine monitoring
and  pre-emptive  therapy  are  not  considered
necessary out of HSCT setting (CIII).13
Influenza
Influenza causes significant morbidity and
mortality  in  immunocompromised  children.
Prevention is based on vaccination. There is
only  one  published  study  in  which  oral
Article
Table 1. Quality of evidence and Strength of recommendations according to the CDC
grading system.23
Quality of evidence Strength of recommendation
IA
Evidence from at least one well-executed Strong evidence for efficacy and 
randomized trial substantial clinical benefit
II Strongly recommended
Evidence from at least one well-designed clinical B
trial without randomization; cohort or case-controlled  Strong or moderate evidence for efficacy, 
analytic studies (preferably from more than one center;  but only limited clinical benefit
multiple time-series studies or dramatic results from  Generally recommended
uncontrolled experiments) C
III Insufficient evidence for efficacy, 
Evidence from opinion of respected authorities based  or efficacy does not outweigh possible
on clinical experience, descriptive studies, or reports  adverse consequences (e.g. drug toxicity
or interactions) from expert committees or cost of chemoprophylaxis or alternative
approaches
Optional
D
Moderate evidence against efficacy or for 
adverse outcome
Generally not recommended
E
Strong evidence against efficacy or for 
adverse outcome
Never recommended
Table 2. Cytomegalovirus prophylaxis.
Immune globulin for prevention of CMV infection or disease is not recommended  EII
Leukemia patients with a lesser degree of immunosuppression do not need 
a specified prophylactic strategy but CMV disease must be in the differential 
diagnosis if symptoms compatible with CMV develop
Routine monitoring and pre-emptive therapy are not considered necessary DIII
in other hematology patients
Routine antiviral prophylaxis is not recommended DIII[Pediatric Reports 2011; 3:e5] [page 15]
Oseltamivir prophylaxis 75 mg once daily for 8
weeks during an influenza season has been
used in the prevention of influenza infection
in  immunocompromised  children  with  few
side-effects. It is a prospective, non-blinded,
non-controlled observational study (CIII).19
There  are  no  large  clinical  trials  about
influenza treatment. Oseltamivir can prevent
progression to pneumonia and can be used in
children starting from 1 year of age, Zanamivir
in  children  aged  >7  years  of  age.  It  is  still
unknown  the  risk  to  develop  resistance  to
antiviral agents.20
Respiratory syncytial virus
Respiratory syncytial virus (RSV) is a com-
mon cause of infection in immunocompetent
and immunocompromised host. The majority
of patients affected by RSV and by other respi-
ratory  virus  experience  mild  symptoms,  but
occasionally  they  can  cause  pneumonia  and
marrow suppression with consequent delay of
chemotherapy administration.3
In a review on a population of children with
acute myeloid leukemia (AML) prevalence of
RSV infection was low, but related mortality
among children with RSV infection was high.
Palivizumab  is  a  humanized  monoclonal
immunoglobulin used for prophylaxis in chil-
dren younger than 2 years of age with chronic
lung disease who require medical therapy and
those born at 32 weeks gestation or earlier; its
use  has  been  suggested  in  some  congenital
heart disease. The authors don’t believe that
prophylactic Palivizumab is routinely indicated
in children with AML because of the low risk to
catch RSV infection; moreover the rarity of this
infection  preclude  the  possibility  of  a  ran-
domised trial (level of evidence DIII).9
About treatment, a Cochrane review on chil-
dren hospitalised for RSV infection underline
that it is not demonstrated a significant bene-
fit of IVIG treatment added to supportive care
compared  with  supportive  care  alone.21 The
role of Ribavirin, an antiviral agent licensed
for severe RSV infection, is unclear too (level
of evidence, CIII).
Parvovirus
Cytopenia caused by chemotherapy is indis-
tinguishable from that associated with infec-
tion  or  other  causes.  A  prospective  study
detected  Parvovirus  B19  DNA  in  pediatric
patients  with  unexpected  cytopenia  during
chemotherapy for ALL; classical symptoms like
erythema  infectiosum  were  absent.  In  some
situations, for example during manteinance,
cytopenia  can  cause  suspension  or  reduce
intensity  of  treatment.  The  authors  suggest
screening  for  parvovirus  B19  in  pediatric
patients with ALL and unexplained cytopenia.
Treatment with IVIG has proven to be success-
ful although some studies could not document
a clear benefit (level of evidence CIII).22
Enterovirus 
In  immunocompromised  children,  entero  -
virus can cause life-theatening infections such
as  myocarditis,  meningitis  and  encephalitis.
Early  diagnosis  and  treatment  with  IVIG
together with supportive care may improve the
outcome. In a retrospective study, children who
received high dose of IVIG (2 gr/kg) developed
early negative viral load versus children treat-
ed with low dose of IVIG (400 mg/kg) (level of
evidence CIII).10
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